This company has been marked as potentially delisted and may not be actively trading. Neuralstem (CUR) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock CUR vs. FRTX, APTO, ONVO, GENE, SQZ, SRNE, KRBP, TCBP, GNCAQ, and GNCAShould you be buying Neuralstem stock or one of its competitors? The main competitors of Neuralstem include Fresh Tracks Therapeutics (FRTX), Aptose Biosciences (APTO), Organovo (ONVO), Genetic Technologies (GENE), SQZ Biotechnologies (SQZ), Sorrento Therapeutics (SRNE), Kiromic BioPharma (KRBP), TC Biopharm (TCBP), Genocea Biosciences (GNCAQ), and Genocea Biosciences (GNCA). These companies are all part of the "medical" sector. Neuralstem vs. Its Competitors Fresh Tracks Therapeutics Aptose Biosciences Organovo Genetic Technologies SQZ Biotechnologies Sorrento Therapeutics Kiromic BioPharma TC Biopharm Genocea Biosciences Genocea Biosciences Fresh Tracks Therapeutics (NASDAQ:FRTX) and Neuralstem (NASDAQ:CUR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability. Which has stronger valuation & earnings, FRTX or CUR? Neuralstem has lower revenue, but higher earnings than Fresh Tracks Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFresh Tracks Therapeutics$10.06M0.56-$5.69M-$1.41-0.66Neuralstem$260K5.86-$4.93MN/AN/A Do insiders and institutionals hold more shares of FRTX or CUR? 25.0% of Fresh Tracks Therapeutics shares are owned by institutional investors. Comparatively, 38.3% of Neuralstem shares are owned by institutional investors. 0.2% of Fresh Tracks Therapeutics shares are owned by insiders. Comparatively, 5.4% of Neuralstem shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more volatility and risk, FRTX or CUR? Fresh Tracks Therapeutics has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500. Comparatively, Neuralstem has a beta of 1.81, meaning that its stock price is 81% more volatile than the S&P 500. Does the media prefer FRTX or CUR? In the previous week, Fresh Tracks Therapeutics' average media sentiment score of 0.00 equaled Neuralstem'saverage media sentiment score. Company Overall Sentiment Fresh Tracks Therapeutics Neutral Neuralstem Neutral Is FRTX or CUR more profitable? Fresh Tracks Therapeutics has a net margin of 0.00% compared to Neuralstem's net margin of -39,417.64%. Fresh Tracks Therapeutics' return on equity of 0.00% beat Neuralstem's return on equity.Company Net Margins Return on Equity Return on Assets Fresh Tracks TherapeuticsN/A N/A N/A Neuralstem -39,417.64%-170.51%-110.16% SummaryNeuralstem beats Fresh Tracks Therapeutics on 5 of the 9 factors compared between the two stocks. Get Neuralstem News Delivered to You Automatically Sign up to receive the latest news and ratings for CUR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CUR vs. The Competition Export to ExcelMetricNeuralstemBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.52M$202.67M$5.49B$9.01BDividend YieldN/AN/A5.38%4.09%P/E RatioN/AN/A27.4220.26Price / Sales5.86223.65407.97121.21Price / CashN/A22.4436.6357.47Price / Book0.115.618.085.67Net Income-$4.93M-$96.61M$3.16B$248.47M Neuralstem Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CURNeuralstemN/A$0.73-0.6%N/A-83.9%$1.52M$260K0.006FRTXFresh Tracks TherapeuticsN/A$0.94-0.5%N/A+0.6%$5.59M$10.06M-0.6620APTOAptose Biosciences1.8364 of 5 starsN/A$6.00+∞N/A$3.66MN/A-0.5831Gap DownHigh Trading VolumeONVOOrganovoN/AN/AN/AN/A$3.47M$122K-2.4020Gap UpGENEGenetic TechnologiesN/A$0.77flatN/AN/A$3.37M$7.66M0.0050High Trading VolumeSQZSQZ BiotechnologiesN/A$0.03flatN/A-24.3%$826K$18.16M-0.011,620SRNESorrento Therapeutics0.7355 of 5 stars$0.00-36.4%N/A-81.7%$772K$60.32M0.00800News CoverageGap DownKRBPKiromic BioPharmaN/AN/AN/AN/A$330KN/A-0.0660Gap DownHigh Trading VolumeTCBPTC BiopharmN/A$0.68-55.8%$48.00+6,948.5%-99.5%$279K$4.76M0.0080High Trading VolumeGNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070 Related Companies and Tools Related Companies FRTX Alternatives APTO Alternatives ONVO Alternatives GENE Alternatives SQZ Alternatives SRNE Alternatives KRBP Alternatives TCBP Alternatives GNCAQ Alternatives GNCA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CUR) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuralstem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuralstem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.